• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Brookline Capital initiated coverage on Adial Pharmaceuticals with a new price target

    10/13/21 11:54:22 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADIL alert in real time by email
    Brookline Capital initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $12.00
    Get the next $ADIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADIL

    DatePrice TargetRatingAnalyst
    11/14/2024$8.00Buy
    Rodman & Renshaw
    10/13/2021$12.00Buy
    Brookline Capital
    6/29/2021$5.00Buy
    Litchfield Hills
    More analyst ratings

    $ADIL
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Adial Pharmaceuticals Inc

      DEFR14A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

      6/27/25 4:06:12 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

      6/18/25 5:10:17 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Adial Pharmaceuticals Inc

      424B5 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

      6/18/25 7:49:11 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

      Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batches of AD04 for US Clinical Trials And NDA Submission GLEN ALLEN, Va., June 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the recent execution of agreements for the production of AD04 (0.33 mg ondansetron tablets), supporting both the

      6/25/25 8:30:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering

      GLEN ALLEN, Va., June 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the pricing of its "reasonable best efforts" public offering for the purchase and sale of 11,100,000 shares of common stock of the Company (or common stock equivalents in lieu thereof), together with Series D warrants to purchase up to 11,100,000 shares of common stock (the "Series D Warrants") and Series E warrants to purchase up to 8,325,000 shares of common stock (the "Series E Warrants"), at a combined offerin

      6/17/25 8:00:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting

      End of Phase 2 Meeting has been Rescheduled for July 29th Meeting to Discuss Upcoming Clinical Development Plan and Protocol Designs Strategic Partnership Discussions Expected to Accelerate Following a Positive FDA Meeting GLEN ALLEN, Va., June 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the submission of the required briefing package for the upcoming End of Phase 2 meeting (EOP2M) with the Food and Drug Administration (FDA). The FDA has rescheduled the meeting which will now

      6/16/25 8:00:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Newman James W. Jr.

      4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      6/2/25 4:01:35 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gilliland Robertson H.

      4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      6/2/25 4:01:36 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Shah Vinay

      4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      6/2/25 4:01:34 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care